Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

European stroke prevention study.

A Lowenthal1

  • 1Universitaire Instelling Antwerpen, Labo Neurochemie, Wilrijk, België.

Acta Neurologica Belgica
|January 1, 1988
PubMed
Summary
This summary is machine-generated.

The European Stroke Prevention Study found that Persantin-Aspirin significantly reduces stroke and vascular death risks by 36.5% in a large patient group. This risk reduction was sustained over two years and proved superior to other anti-aggregation prevention methods.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acute liver failure complicating ductal breast carcinoma: two cases and literature review.

Scandinavian journal of gastroenterology·2003
Same author

Ludo Van Bogaert (1897-1989).

Journal of medical biography·2001
Same author

Gingival hypertrophy due to drugs.

The Israel Medical Association journal : IMAJ·2001
Same author

Thiopurine methyltransferase activity in the Jewish population of Israel.

European journal of clinical pharmacology·2001
Same author

Harold Hillman MBBS MRCS LRCP BSc PhD.

Resuscitation·2000
Same author

Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group.

Epilepsia·2000
Same journal

Synergistic pain relief in cervical radiculopathy: A randomized trial of topical methylcobalamin gel with phonophoresis and Mulligan mobilization.

Acta neurologica Belgica·2026
Same journal

Characterizing cranial tremors in a case of spinocerebellar ataxia type 12: a unique positional tremor.

Acta neurologica Belgica·2026
Same journal

A case of coexistence of spinal intradural capillary hemangioma and craniocervical junction dural arteriovenous fistula.

Acta neurologica Belgica·2026
Same journal

Comment on "Content quality and reliability of youtube exercise videos for parkinson's disease".

Acta neurologica Belgica·2026
Same journal

A novel CHMP2B variant of uncertain significance in a patient with apathy, hyperorality, and mild language impairment.

Acta neurologica Belgica·2026
Same journal

Photon-counting CT-angiography in comparison to digital subtraction angiography and MR-angiography for assessing intra-aneurysmal flow disrupting devices.

Acta neurologica Belgica·2026
See all related articles

Area of Science:

  • Cardiovascular Medicine
  • Neurology
  • Clinical Trials

Background:

  • Stroke and vascular death represent significant global health burdens.
  • Anti-aggregation therapies are crucial in preventing vascular events.
  • Previous studies have explored various anti-aggregation agents with varying efficacy.

Purpose of the Study:

  • To evaluate the efficacy of the Persantin-Aspirin association in reducing stroke and vascular death.
  • To compare the effectiveness of Persantin-Aspirin with other anti-aggregation prevention strategies.
  • To determine the minimum patient population required for statistically significant results in such studies.

Main Methods:

  • A large-scale clinical trial involving 2500 patients.
  • Two-year follow-up period to assess long-term risk reduction.

Related Experiment Videos

  • Comparative analysis against existing anti-aggregation prevention studies.

    • Main Results:

    • A significant 36.5% reduction in stroke and vascular death risks was observed.
    • The observed risk reduction was consistent in both men and women.
    • The efficacy of Persantin-Aspirin surpassed that of other anti-aggregation interventions studied.
    • Studies with fewer than 600 patients were deemed insufficient for detecting significant differences.

    Conclusions:

    • The combination of Persantin and Aspirin is a highly effective strategy for stroke and vascular death prevention.
    • This therapy offers superior risk reduction compared to other anti-aggregation methods.
    • Robust clinical trial design necessitates a substantial patient cohort (over 600) for reliable outcome assessment.